Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.

Cognitive deficits in schizophrenia remain an unmet clinical need. Improved understanding of the neuro- and psychopathology of these deficits depends on the availability of carefully validated animal models which will assist the development of novel therapies. There is much evidence that at least some of the pathology and symptomatology (particularly cognitive and negative symptoms) of schizophrenia results from a dysfunction of the glutamatergic system which may be modelled in animals through the use of NMDA receptor antagonists. The current review examines the validity of this model in rodents. We review the ability of acute and sub-chronic treatment with three non-competitive NMDA antagonists; phencyclidine (PCP), ketamine and MK801 (dizocilpine) to produce cognitive deficits of relevance to schizophrenia in rodents and their subsequent reversal by first- and second-generation antipsychotic drugs. Effects of NMDA receptor antagonists on the performance of rodents in behavioural tests assessing the various domains of cognition and negative symptoms are examined: novel object recognition for visual memory, reversal learning and attentional set shifting for problem solving and reasoning, 5-Choice Serial Reaction Time for attention and speed of processing; in addition to effects on social behaviour and neuropathology. The evidence strongly supports the use of NMDA receptor antagonists to model cognitive deficit and negative symptoms of schizophrenia as well as certain pathological disturbances seen in the illness. This will facilitate the evaluation of much-needed novel pharmacological agents for improved therapy of cognitive deficits and negative symptoms in schizophrenia.

[1]  I. Nimmo-Smith,et al.  Hypofrontality in schizophrenia: a meta‐analysis of functional imaging studies , 2004, Acta psychiatrica Scandinavica.

[2]  N. Idris,et al.  D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. , 2009, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.

[3]  J. Addington,et al.  Neurocognitive and social functioning in schizophrenia and other diagnoses , 2001, Schizophrenia Research.

[4]  G. Higgins,et al.  Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task , 2000, Behavioural Brain Research.

[5]  B. Glenthøj,et al.  Evaluation of a neurodevelopmental model of schizophrenia—Early postnatal PCP treatment in attentional set-shifting , 2008, Behavioural Brain Research.

[6]  R. Dias,et al.  Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat—a back translational study , 2008, Psychopharmacology.

[7]  M. Haut,et al.  On the nature of Wisconsin Card Sorting Test performance in schizophrenia , 1996, Psychiatry Research.

[8]  B. Moghaddam,et al.  Distinct Contributions of Glutamate Receptor Subtypes to Cognitive Set‐Shifting Abilities in the Rat , 2003, Annals of the New York Academy of Sciences.

[9]  A. Becker,et al.  Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia , 2004, Neuroscience.

[10]  A. Mortimer,et al.  Stability of set-shifting and planning abilities in patients with schizophrenia , 2004, Psychiatry Research.

[11]  Joseph P. Huston,et al.  The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents , 2007, Neuroscience & Biobehavioral Reviews.

[12]  G. Reynolds,et al.  Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat , 2010, Behavioural Brain Research.

[13]  Yuko Fujita,et al.  Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[14]  T. Robbins,et al.  Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage , 1999, Schizophrenia Research.

[15]  L. Saksida,et al.  Effects of Subchronic Phencyclidine (PCP) Treatment on Social Behaviors, and Operant Discrimination and Reversal Learning in C57BL/6J Mice , 2008, Front. Behav. Neurosci..

[16]  D. Dorsa,et al.  Social Interaction Deficits Caused by Chronic Phencyclidine Administration are Reversed by Oxytocin , 2005, Neuropsychopharmacology.

[17]  A. Sampson,et al.  Gene Expression Deficits in a Subclass of GABA Neurons in the Prefrontal Cortex of Subjects with Schizophrenia , 2003, The Journal of Neuroscience.

[18]  T. Robbins,et al.  Behavioural rigidity and rule-learning deficits following isolation-rearing in the rat: neurochemical correlates , 1991, Behavioural Brain Research.

[19]  R. Roesler,et al.  Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats , 2005, Behavioural Brain Research.

[20]  T. Robbins,et al.  Effects of orbitofrontal, infralimbic and prelimbic cortical lesions on serial spatial reversal learning in the rat , 2007, Behavioural Brain Research.

[21]  R. Depoortère,et al.  F15063, a compound with D2/D3 antagonist, 5‐HT1A agonist and D4 partial agonist properties: (III) Activity in models of cognition and negative symptoms , 2007, British journal of pharmacology.

[22]  Paul J. Fletcher,et al.  Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex , 2005, Psychopharmacology.

[23]  M. Kurachi,et al.  NC-1900, an arginine–vasopressin analogue, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: Therapeutic implications for schizophrenia , 2005, Brain Research.

[24]  J John Mann,et al.  The GABAergic system in schizophrenia. , 2002, The international journal of neuropsychopharmacology.

[25]  C. Beasley,et al.  Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics , 1997, Schizophrenia Research.

[26]  G. Reynolds,et al.  The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm , 2006, Behavioural Brain Research.

[27]  A. Markou,et al.  Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats , 2007, Psychopharmacology.

[28]  R. Roth,et al.  Subchronic Phencyclidine Administration Reduces Mesoprefrontal Dopamine Utilization and Impairs Prefrontal Cortical-Dependent Cognition in the Rat , 1997, Neuropsychopharmacology.

[29]  Trevor W. Robbins,et al.  Local glutamate receptor antagonism in the rat prefrontal cortex disrupts response inhibition in a visuospatial attentional task , 2005, Psychopharmacology.

[30]  J. Delacour,et al.  A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data , 1988, Behavioural Brain Research.

[31]  Wolfgang Hauber,et al.  Orbital prefrontal cortex and guidance of instrumental behaviour in rats under reversal conditions , 2003, Behavioural Brain Research.

[32]  A. Grace,et al.  Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. , 2005, Schizophrenia bulletin.

[33]  H. Schroeder,et al.  Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[34]  M Marmot,et al.  Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort , 1994, The Lancet.

[35]  R. Roth,et al.  The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.

[36]  G. Reynolds,et al.  Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat , 2008, Behavioural Brain Research.

[37]  M. Kiefer,et al.  Executive control is disturbed in schizophrenia: evidence from event-related potentials in a Go/NoGo task , 2000, Biological Psychiatry.

[38]  G. Winger.  Dopamine antagonist effects on behavior maintained by cocaine and alfentanil in rhesus monkeys , 1994, Behavioural pharmacology.

[39]  T. Robbins,et al.  Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia , 2004, Psychopharmacology.

[40]  E. Murphy,et al.  PDE10A inhibition reverses subchronic PCP‐induced deficits in attentional set‐shifting in rats , 2005, The European journal of neuroscience.

[41]  K. Bogeso,et al.  Strategies for pharmacotherapy of schizophrenia , 2008 .

[42]  H E ROSVOLD,et al.  A continuous performance test of brain damage. , 1956, Journal of consulting psychology.

[43]  C. Large,et al.  Behavioral Neuroscience , 2022 .

[44]  B. Everitt,et al.  AMPA‐induced Lesions of the Basal Forebrain Differentially Affect Cholinergic and Non‐cholinergic Neurons: Lesion Assessment Using Quantitative In Situ Hybridization Histochemistry , 1995, The European journal of neuroscience.

[45]  A. C. Roberts,et al.  Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: Evidence for a specific attentional dysfunction , 1989, Neuropsychologia.

[46]  W. Carlezon,et al.  Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats , 2009, Neuropharmacology.

[47]  R. Joosten,et al.  The NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats , 2003, Neuroreport.

[48]  B. Glenthøj,et al.  Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia—sub-chronic and early postnatal PCP treatment in attentional set-shifting , 2009, Psychopharmacology.

[49]  J. Neill,et al.  Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia , 2011, European Neuropsychopharmacology.

[50]  A. Newman-Tancredi,et al.  Effects of novel antipsychotics with mixed D2 antagonist/5-HT1A agonist properties on PCP-induced social interaction deficits in the rat , 2005, Neuropharmacology.

[51]  Kenneth M. Johnson,et al.  Postnatal Phencyclidine Administration Selectively Reduces Adult Cortical Parvalbumin-Containing Interneurons , 2008, Neuropsychopharmacology.

[52]  R. Roth,et al.  Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. , 1997, Science.

[53]  G. Reynolds,et al.  The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat , 2003, Journal of psychopharmacology.

[54]  K. Hashimoto,et al.  d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats , 2008, Behavioural Brain Research.

[55]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[56]  J. Newcomer,et al.  NMDA receptor hypofunction model of schizophrenia. , 1999, Journal of psychiatric research.

[57]  V. Brown,et al.  Difficulty Overcoming Learned Non‐reward during Reversal Learning in Rats with Ibotenic Acid Lesions of Orbital Prefrontal Cortex , 2007, Annals of the New York Academy of Sciences.

[58]  B. Bogerts,et al.  Haloperidol and clozapine decrease S100B release from glial cells , 2010, Neuroscience.

[59]  I. Whishaw,et al.  Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients. , 1983, The Journal of nervous and mental disease.

[60]  T. Robbins,et al.  Lesions of the medial and lateral striatum in the rat produce differential deficits in attentional performance. , 2001, Behavioral neuroscience.

[61]  T. Robbins,et al.  Dissociable aspects of performance on the 5-choice serial reaction time task following lesions of the dorsal anterior cingulate, infralimbic and orbitofrontal cortex in the rat: differential effects on selectivity, impulsivity and compulsivity , 2003, Behavioural Brain Research.

[62]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[63]  Kevin L Quick,et al.  Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase , 2007, Science.

[64]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[65]  T. Dinan,et al.  Executive function in schizophrenia: what impact do antipsychotics have? , 2007, Human psychopharmacology.

[66]  B. Moghaddam,et al.  Systemic and prefrontal cortical NMDA receptor blockade differentially affect discrimination learning and set-shift ability in rats. , 2005, Behavioral neuroscience.

[67]  J. Neill,et al.  Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats , 2010, Behavioural Brain Research.

[68]  M. Chan,et al.  Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice , 2008, Psychopharmacology.

[69]  E. G. Jones,et al.  Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. , 1995, Archives of general psychiatry.

[70]  T. Nabeshima,et al.  Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors , 2008, Psychopharmacology.

[71]  V. Brown,et al.  Medial Frontal Cortex Mediates Perceptual Attentional Set Shifting in the Rat , 2000, The Journal of Neuroscience.

[72]  J. Muir,et al.  The cerebral cortex of the rat and visual attentional function: dissociable effects of mediofrontal, cingulate, anterior dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task. , 1996, Cerebral cortex.

[73]  K. Marshall,et al.  Oestradiol attenuates the cognitive deficit induced by acute phencyclidine treatment in mature female hooded-Lister rats , 2008, Journal of psychopharmacology.

[74]  A. Sleight,et al.  5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism , 2004, Neuropharmacology.

[75]  N. Pitsikas,et al.  Effects of sub-anesthetic doses of ketamine on rats' spatial and non-spatial recognition memory , 2008, Neuroscience.

[76]  F. Benes,et al.  A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives , 1998, Biological Psychiatry.

[77]  A. Markou,et al.  Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment , 2009, Pharmacology Biochemistry and Behavior.

[78]  M. Behrens,et al.  Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia , 2008, The Journal of Neuroscience.

[79]  M. Stanton,et al.  NMDA receptor antagonism impairs reversal learning in developing rats. , 2006, Behavioral neuroscience.

[80]  B. Cornblatt,et al.  Impaired attention, genetics, and the pathophysiology of schizophrenia. , 1994, Schizophrenia bulletin.

[81]  M. Laruelle,et al.  Baseline and Amphetamine-Stimulated Dopamine Activity Are Related in Drug-Naïve Schizophrenic Subjects , 2009, Biological Psychiatry.

[82]  B. Everitt,et al.  AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[83]  J. Kemp,et al.  Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition , 2003, Neuropharmacology.

[84]  F. Sams-Dodd.  Distinct effects of d‐amphetamine and phencyclidine on the social behaviour of rats , 1995, Behavioural pharmacology.

[85]  Y. Tabuchi,et al.  Effect of MK‐801 on gene expressions in the amygdala of rats , 2008, Synapse.

[86]  J. Neill,et al.  Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat , 2010, Behavioural Brain Research.

[87]  B. Morris,et al.  PCP: from pharmacology to modelling schizophrenia. , 2005, Current opinion in pharmacology.

[88]  H. Möller.  Management of the Negative Symptoms of Schizophrenia , 2012, CNS drugs.

[89]  E. A. Berg,et al.  A simple objective technique for measuring flexibility in thinking. , 1948, The Journal of general psychology.

[90]  F. Doré,et al.  Rule shift under long-term PCP challenge in rats , 2006, Behavioural Brain Research.

[91]  F. Sams-Dodd.  A Test of the Predictive Validity of Animal Models of Schizophrenia Based on Phencyclidine and D-Amphetamine , 1998, Neuropsychopharmacology.

[92]  G. Thaker,et al.  Advances in schizophrenia , 2001, Nature Medicine.

[93]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[94]  J. Neill,et al.  Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats—A preliminary investigation , 2008, Behavioural Brain Research.

[95]  J. Neill,et al.  A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats , 2008, Behavioural Brain Research.

[96]  Philip D. Harvey,et al.  Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia , 2012, Drugs.

[97]  G. Reynolds,et al.  Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat , 2006, Journal of psychopharmacology.

[98]  T. Goldberg,et al.  Neurocognitive Deficits in Schizophrenia , 2007 .

[99]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[100]  A. Becker,et al.  Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[101]  David R. Thomas,et al.  Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat , 2009, Psychopharmacology.

[102]  Yuko Fujita,et al.  Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: Role of serotonin 5-HT1A receptors , 2008, European Neuropsychopharmacology.

[103]  E. Jodo,et al.  Phencyclidine affects firing activity of basolateral amygdala neurons related to social behavior in rats , 2009, Neuroscience.

[104]  J. Podhorná,et al.  Subchronic phencyclidine treatment impairs performance of C57BL/6 mice in the attentional set-shifting task , 2004, Behavioural pharmacology.

[105]  J. Coyle,et al.  Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis , 2006, Cellular and Molecular Neurobiology.

[106]  N. Andreasen,et al.  Positive and negative symptoms in schizophrenia. A critical reappraisal. , 1990, Archives of general psychiatry.

[107]  D L Braff,et al.  The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. , 1991, Archives of general psychiatry.

[108]  T. Robbins,et al.  The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry , 2002, Psychopharmacology.

[109]  K. Fone,et al.  Behavioural and neurochemical effects of post-weaning social isolation in rodents—Relevance to developmental neuropsychiatric disorders , 2008, Neuroscience & Biobehavioral Reviews.

[110]  Anil K Malhotra,et al.  Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.

[111]  Peter B. Jones,et al.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.

[112]  J. Neill,et al.  Improvement of phencyclidine-induced social behaviour deficits in rats: Involvement of 5-HT1A receptors , 2008, Behavioural Brain Research.

[113]  B. Grayson,et al.  Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat , 2007, Behavioural Brain Research.

[114]  A. Carlsson,et al.  Differential effects of the N-methyl-d-aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice , 2007, Neuroscience.

[115]  B. Morris,et al.  Induction of Metabolic Hypofunction and Neurochemical Deficits after Chronic Intermittent Exposure to Phencyclidine: Differential Modulation by Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[116]  V. Brown,et al.  Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat , 2003, Behavioural Brain Research.

[117]  C. Large,et al.  Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? , 2007, Journal of psychopharmacology.

[118]  Boyer D. Winters,et al.  Object recognition memory: Neurobiological mechanisms of encoding, consolidation and retrieval , 2008, Neuroscience & Biobehavioral Reviews.

[119]  J. Arnt,et al.  Reversal of Subchronic PCP-Induced Deficits in Attentional Set Shifting in Rats by Sertindole and a 5-HT6 Receptor Antagonist: Comparison Among Antipsychotics , 2008, Neuropsychopharmacology.

[120]  J. Meador-Woodruff,et al.  NMDA receptors and schizophrenia. , 2007, Current opinion in pharmacology.

[121]  Yogesh K. Dwivedi,et al.  Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. , 2000, Archives of general psychiatry.

[122]  C. Beasley,et al.  Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins , 2002, Biological Psychiatry.

[123]  J. S. Sutcliffe,et al.  Influence of gender on working and spatial memory in the novel object recognition task in the rat , 2007, Behavioural Brain Research.

[124]  R. Nadal,et al.  Acute effects of ketamine in the holeboard, the elevated‐plus maze, and the social interaction test in Wistar rats , 1997, Depression and anxiety.

[125]  J. Rung,et al.  (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[126]  R. Steinpreis.  The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis , 1996, Behavioural Brain Research.

[127]  B. Kolb,et al.  The Cerebral cortex of the rat , 1990 .

[128]  S. Floresco,et al.  Neural circuits subserving behavioral flexibility and their relevance to schizophrenia , 2009, Behavioural Brain Research.

[129]  E. Benarroch.  Executive Control , 2022, Neuroscience for Clinicians.

[130]  M. Carli,et al.  Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC , 2008, Psychopharmacology.

[131]  Paul J. Harrison,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Genes for Schizophrenia? Recent Findings and Their Pathophysiological Implications , 2022 .

[132]  F. Benes,et al.  Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain , 1996, Synapse.

[133]  D. Velligan,et al.  Executive function in schizophrenia. , 1999, Seminars in clinical neuropsychiatry.

[134]  F. Doré,et al.  Impaired social motivation and increased aggression in rats subchronically exposed to phencyclidine , 2009, Physiology & Behavior.

[135]  A. Sampson,et al.  Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. , 2000, Archives of general psychiatry.

[136]  S. Nakagawa,et al.  Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats , 2007, Psychopharmacology.

[137]  F. Sams-Dodd.  Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. , 1997, Behavioural pharmacology.

[138]  C. Large,et al.  Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and d-amphetamine in the rat , 2005, Psychopharmacology.

[139]  Brian J. Morris,et al.  Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia , 2005, Psychopharmacology.

[140]  Howard Carter,et al.  A PRELIMINARY INVESTIGATION , 2010 .

[141]  J. Neill,et al.  Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms , 2009, Psychopharmacology.

[142]  T. Nabeshima,et al.  Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment , 2001, Neuroreport.

[143]  Gavin P. Reynolds,et al.  A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia , 2002, Schizophrenia Research.

[144]  P. Seeman,et al.  Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.

[145]  Robert W. McCarley,et al.  A Pharmacological Model for Psychosis Based on N-methyl-D-aspartate Receptor Hypofunction: Molecular, Cellular, Functional and Behavioral Abnormalities , 2006, Biological Psychiatry.

[146]  B. Morris,et al.  Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats , 2008, Psychopharmacology.

[147]  M. Carli,et al.  Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU2/3 receptor agonist LY379268 , 2005, Psychopharmacology.

[148]  J. Hagan,et al.  Predicting drug efficacy for cognitive deficits in schizophrenia. , 2005, Schizophrenia bulletin.

[149]  A. Bespalov,et al.  Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment , 2007, Psychopharmacology.

[150]  E. Roberts.  Prospects for research on schizophrenia. An hypotheses suggesting that there is a defect in the GABA system in schizophrenia. , 1972, Neurosciences Research Program bulletin.

[151]  Yuko Fujita,et al.  Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. , 2005, European journal of pharmacology.

[152]  D. Lewis,et al.  Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.

[153]  K. Haramy.  A PRELIMINARY INVESTIGATION-OF , 2001 .

[154]  T. Sejnowski,et al.  Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? , 2009, Neuropharmacology.

[155]  A. Cools,et al.  Animal models for the negative symptoms of schizophrenia , 2000, Behavioural pharmacology.

[156]  F. Sams-Dodd.  Phencyclidine in the Social Interaction Test: An Animal Model of Schizophrenia with Face and Predictive Validity , 1999, Reviews in the neurosciences.

[157]  A. G. Smith,et al.  The Dopamine D3/D2 Receptor Agonist 7-OH-DPAT Induces Cognitive Impairment in the Marmoset , 1999, Pharmacology Biochemistry and Behavior.

[158]  W. Carlezon,et al.  Sensitivity of the Five-Choice Serial Reaction Time Task to the Effects of Various Psychotropic Drugs in Sprague-Dawley Rats , 2007, Biological Psychiatry.

[159]  T. Minamoto,et al.  Brief exposure to methamphetamine (METH) and phencyclidine (PCP) during late development leads to long-term learning deficits in rats , 2009, Brain Research.

[160]  H. Häfner,et al.  The epidemiology of onset and course of schizophrenia , 2000, European Archives of Psychiatry and Clinical Neuroscience.

[161]  Yukihiro Noda,et al.  Phencyclidine animal models of schizophrenia: Approaches from abnormality of glutamatergic neurotransmission and neurodevelopment , 2007, Neurochemistry International.

[162]  G. Reynolds,et al.  Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia , 1990, Biological Psychiatry.

[163]  Ben Grayson,et al.  Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. , 2010, The international journal of neuropsychopharmacology.

[164]  L. Cahill.  Why sex matters for neuroscience , 2006, Nature Reviews Neuroscience.

[165]  R. Depoortère,et al.  SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats , 2004, Neuropharmacology.

[166]  S. Lawrie,et al.  Brain abnormality in schizophrenia , 1998, British Journal of Psychiatry.

[167]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[168]  D. Rujescu,et al.  Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism , 2007, Schizophrenia Research.

[169]  Jared W. Young,et al.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. , 2009, Pharmacology & therapeutics.

[170]  R. Murray,et al.  Meta-analysis of regional brain volumes in schizophrenia. , 2000, The American journal of psychiatry.

[171]  A. Carlsson,et al.  EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.